Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort.

Autor: César Garriga, Patricia García de Olalla, Josep M Miró, Inma Ocaña, Hernando Knobel, Maria Jesús Barberá, Victoria Humet, Pere Domingo, Josep M Gatell, Esteve Ribera, Mercè Gurguí, Andrés Marco, Joan A Caylà, Barcelona HIV/AIDS working group

Publikováno v: PLoS ONE, Vol 10, Iss 12, p e0145701 (2015)

INTRODUCTION:Antiretroviral therapy has led to a decrease in HIV-related mortality and to the emergence of non-AIDS defining diseases as competing causes of death. This study estimates the HIV mortality rate and their risk factors with regard to diff

Externí odkaz: https://doaj.org/article/219b0d5da10440ff96ccf0117b81042d

Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment

Autor: Joaquin Burgos, Inma Ocaña, Jordi Navarro, Vicenç Falcó, Adrian Curran, Esteban Ribera, Manuel Crespo, Ariadna Torrella

Publikováno v: Antiviral therapy. 22(1)

An HIV-infected patient treated with tenofovir disoproxil fumarate/emtricitabine/elvitegravir/cobicistat developed severe acute ischaemia of both legs during a migraine episode. After being interrogated he admitted taking an ergotamine-containing pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ef3dd80adc182b211a71d47d24514c
https://pubmed.ncbi.nlm.nih.gov/27546463

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients

Autor: Inma Ocaña, Gracia Mateo, Mar Gutirerrez, Adrian Curran, Elisabet Deig, Rosa M Lopez, Pere Domingo, Manuel Crespo, Esteban Ribera, Arkaitz Imaz

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

To evaluate the virological efficacy, safety, tolerability and pharmacokinetics of a regimen containing 900/100 mg of ritonavir-boosted darunavir once daily in patients with antiretroviral experience but no darunavir resistance. An observational, pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0a56c11ec0f58f8c5585f8bb466304
https://doi.org/10.1093/jac/dkq295

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain

Autor: Adria Curran, Maria Feijoo, Ariadna Torrella, Esteban Ribera, Estrella Caballero, Jordi Navarro, Vicenç Falcó, Inma Ocaña, Mercè Pérez, Joaquin Burgos, Manel Crespo

Publikováno v: AIDS patient care and STDs. 28(10)

Several studies have shown the importance of adherence to highly active antiretroviral therapy (HAART) in achieving HIV-1 suppression. However, most have focused on naïve patients and do not assess the impact of HAART on viral load (VL). Our aim was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0155260c380e98c54611f8cf59aae738
https://pubmed.ncbi.nlm.nih.gov/25111167

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection

Autor: Marjorie Diaz, Enrique Ruiz de Gopegui, Vicenç Falcó, M. Àngels Ribas, Sara Villar del Saz, M Riera, Estrella Caballero, Adrian Curran, Arkaitz Imaz, Inma Ocaña, Manel Crespo, Esteban Ribera

Publikováno v: Journal of acquired immune deficiency syndromes (1999). 52(3)

Background: Boosted darunavir (DRV/r) plus etravirine (ETR), in DUET trials, and raltegravir, in BENCHMRK trials, showed high rates of virologic response in patients with multidrug-resistant HIV-1 infection, particularly when associated with two more

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca82adde79e4c454a18135dcc563688a
https://pubmed.ncbi.nlm.nih.gov/19654552